ANTON FURMAN: Open Payments
NPI 1699167163 · LEVITTOWN, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$829 in 35 payments from 14 companies in 2025. Trend: 2023 $534 · 2024 $722 · 2025 $829
Food & beverage: $829
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 8 | $154 |
| Neurocrine BioSciences, Inc. | 1 | $139 |
| Sumitomo Pharma America, Inc. | 5 | $102 |
| PFIZER INC. | 4 | $68 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $61 |
| Lundbeck LLC | 2 | $46 |
| ACADIA Pharmaceuticals Inc | 2 | $45 |
| Teva Pharmaceuticals USA, Inc. | 1 | $37 |
| ABBVIE INC. | 2 | $36 |
| Vanda Pharmaceuticals Inc. | 2 | $36 |
Products named: REXULTI, INGREZZA, GEMTESA, CAPLYTA, NUPLAZID, AUSTEDO XR, VRAYLAR, FANAPT.
Industry payments across PA — which companies pay providers there.
